Frontiers in Immunology · 2022 · 10 citations · 37 references
Veterinary MedicineImmunologyInfectious DiseasesImmunizationVaccine BiotechnologyVaccinologyDna VaccinesNucleic Acid VaccinesRecombinant Vaccine DevelopmentVaccinationVaccine-preventable DiseasesViral VaccinesDeoxyribonucleic Acid (Dna) VaccineElectroporationPlasmid Gene ExpressionPlasmid Vaccine VectorsSelectable Marker GenesVaccine Candidate AntigensViral Mutation RateViral Replication Control
SARS-CoV-2 vaccines currently in use have contributed to controlling the COVID-19 pandemic. Notwithstanding, the high mutation rate, fundamentally in the spike glycoprotein (S), is causing the emergence of new variants. Solely utilizing this antigen is a drawback that may reduce the efficacy of these vaccines. Herein we present a DNA vaccine candidate that contains the genes encoding the S and the nucleocapsid (N) proteins implemented into the non-replicative mammalian expression plasmid vector, pPAL. This plasmid lacks antibiotic resistance genes and contains an alternative selectable marker for production. The S gene sequence was modified to avoid furin cleavage (Sfs). Potent humoral and cellular immune responses were observed in C57BL/6J mice vaccinated with pPAL-Sfs + pPAL-N following a prime/boost regimen by the intramuscular route applying in vivo electroporation. The immunogen fully protected K18-hACE2 mice against a lethal dose (10 5 PFU) of SARS-CoV-2. Viral replication was completely controlled in the lungs, brain, and heart of vaccinated mice. Therefore, pPAL-Sfs + pPAL-N is a promising DNA vaccine candidate for protection from COVID-19.
37
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang, Yeming Wang, Xingwang Li et al. · The Lancet · 2020 · 51.8K citations · Full text